Chronic respiratory infections in people with cystic fibrosis (CF) are increasingly difficult to treat in the context of antimicrobial resistance, driving renewed interest in bacteriophage (phage) therapy. This presentation will describe how the Trailfinder-CF programme is addressing key translational challenges to enable the integration of phage therapy into respiratory care. I will outline approaches to support access for patients requiring phage therapy, including the development of clinical pathways for compassionate use and the development of target product profiles (TPPs) to guide the standardisation, clinical development, and regulatory alignment of phage therapeutics. Efforts to expand and curate clinically relevant phage biobanks targeting unusual respiratory organisms will be discussed alongside studies investigating phage efficacy within the lung environment, including activity in mucus and biofilms. Advances in delivery, dosing, and formulation will be highlighted, with a focus on inhaled approaches and immunogenicity at the site of infection. Rapid and novel diagnostics are also being developed and optimised to detect susceptibility the emergence of resistance in the clinical. In addition, public engagement activities will be showcased, including citizen science-inspired undergraduate practicals designed to build awareness and capacity in the field. Overall, this work illustrates a coordinated, multidisciplinary strategy to advance phage therapy for CF and other chronic respiratory infections.